论文部分内容阅读
血透析病人具有较高的乙型肝炎感染率并易成为传染性强的带毒者,研究表明,这种病人对血源性乙型肝炎疫苗(PDV)的血清阳转率低于健康人。作者用比利时SmithKline Biologicals公司研制的重组酵母源性乙型肝炎疫苗(YDV)以不同剂量和免疫程序接种血透析病人,观察其免疫应答。经体检采血检测HBsAg、抗-HBs和抗-HBc均为阴性的血透析病人作为研究对象,共计271例(男女性比例为1.42:1),平均年龄51.4岁。以不同组别按20μg或40μg的单一剂量,接种程序为0、1、6月3个剂量或0、1、2、6月或0、1、2和12月4个剂量分别接种YDV。每次接种后观察3天副反应,并在每次接种后的1或2个月采血;血清样品检测抗-HBs、HBsAg和抗-HBc。其
Hemodialysis patients have a high rate of hepatitis B infection and are predisposed to become highly contagious carriers. Studies have shown that this patient has a lower seroconversion rate to blood-borne hepatitis B vaccine (PDV) than healthy people. The authors used a recombinant yeast-derived hepatitis B vaccine (YDV) developed by SmithKline Biologicals in Belgium to vaccinate hemodialysis patients at various doses and immunizations to observe their immune response. A total of 271 hemodialysis patients (negative for HBsAg, anti-HBs and anti-HBc) were enrolled in this study. There were 271 cases (male / female ratio: 1.42: 1) with mean age of 51.4 years. YDV was inoculated separately in different groups at a single dose of 20 μg or 40 μg with three different doses of 0, 1, and June, or 0, 1, 2, 6, or 0, 1, 2, Side effects were observed for 3 days after each inoculation and blood was collected 1 or 2 months after each inoculation; serum samples were tested for anti-HBs, HBsAg and anti-HBc. its